Dermatology Times, May 2021 (Vol. 42, No. 5)

Prescribing biologics can require a complex approval and claims process. Creating a tiered system based on office workload can help practices understand and allocate staff time. Outsourcing approvals to pharmacies where possible can also streamline the process.

Thanks to targeted drugs in early-stage development, patients with generalized pustular psoriasis (GPP) will one day likely have FDA-approved treatments for the disease, according to one expert.

A new generation of inhibitors take aim at key sources of inflammation.

In this month's Cosmetic Conundrums column, Chief Medical Editor of Dermatology Times®, Zoe Diana Draelos, MD, answers a few common questions on how to treat eye issues.

Dermatologists have a variety of topicals to choose from, but other options are on the horizon to add to this armamentarium.

In this month's Legal Eagle article, David J. Goldberg, MD, JD, examines physicians being sued for using injectables for off-label procedures, such as for oily skin.

Novel biologics are moving into off-label indications to expand the dermatologic armamentarium for a broad range of inflammatory skin diseases.

Sunscreen is a necessary preventive tool. However, there are concerns about UV agent absorption, environmental impact, and possible correlations with frontal fibrosing alopecia (FFA). Here is a look at whether those worries are justified by research.

Recent therapeutic advances in topical and systemic therapy offer new options for cases that have not responded to established treatment approaches.

Each month, Dermatology Times® features a roundup of products trending in skin care. Click here to find out what products are trending for the month of May.

Experts in core dermatological specialties share their insights on the game-changing research and innovation that advancing skin disease management and patient care.

In a presentation at the American Academy of Dermatology Virtual Meeting, Marcia S. Driscoll, MD, PharmD, gave guidelines for diagnosing and treating four dermatoses of pregnancy.

Thanks to new drug approvals, medical management is replacing surgery as the first-line treatment for inflammation caused by hidradenitis suppurativa. However, surgery is often necessary to relieve pain related to tunnels.

Patients of color make up a growing market for aesthetic dermatology. Physicians must learn how to tailor treatments and assess skin of color risk to best serve this emerging patient population. Doing so will deliver positive outcomes and drive patient satisfaction.

Telemedicine flourished among dermatology practices in the wake of COVID-19. But as the world tentatively reopens, questions about connectivity, regulations, and payment will have to be addressed before physicians decide what role virtual visits will play in their practices.

Futuristic tools including robotics and new types of lasers are just some of the therapeutic innovations aimed at slowing hair loss and increasing hair growth.

Recent research shows prolonged face-mask usage leads to negative quality-of-life impact and worsening of disease for rosacea.

Topical microtubule inhibitor, tirbanibulin (Klisyri, Almirall), demonstrates positive results for treating actinic keratosis (AK) of the face and scalp, according recently published data from two phase 3 studies.